International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study

Buist, A. Sonia; McBurnie, Mary Ann; Vollmer, William M.; Gillespie, Suzanne M.; Burney, Peter; Mannino, David M.; Menezes, Ana Maria Baptista; Sullivan, Sean D.; Lee, Todd A.; Weiss, Kevin B.; Jensen, Robert L.; Marks, Guy B.; Gulsvik, Amund; Niżankowska‐Mogilnicka, Ewa

doi:10.1016/s0140-6736(07)61377-4

Cited by 1,890 publications

(1,640 citation statements)

References 28 publications

Supporting

Mentioning

1,447

Contrasting

Unclassified

117

Order By: Relevance

“…The questionnaire was adapted from standardized and validated questionnaires 6,7 which are widely used in other respiratory epidemiological studies in Europe and Asia 9 .…”

Section: Discussionmentioning

confidence: 99%

“…We obtained data regarding respiratory health using a standardized questionnaire which included sections from the American Thoracic Society Division of Lung Diseases (ATS/DLD) 6 , European Community Respiratory Health Survey II 7 and Lung Health Study instruments 8 . This questionnaire has been used to investigate respiratory diseases and symptoms 3,9 in a number of countries, including Brazil 5 . Questions related to the presence of respiratory symptoms, self-diagnosis of other chronic diseases, such as asthma, heart disease, systemic arterial hypertension, diabetes, lung cancer, stroke and gastritis or ulcers.…”

Section: Questionnaire and Evaluationsmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of self-reported chronic diseases in individuals over the age of 40 in São Paulo, Brazil: the Platino study

et al. 2012

View full text Add to dashboard Cite

“…The questionnaire was adapted from standardized and validated questionnaires 6,7 which are widely used in other respiratory epidemiological studies in Europe and Asia 9 .…”

Section: Discussionmentioning

confidence: 99%

Section: Questionnaire and Evaluationsmentioning

confidence: 99%

Prevalence of self-reported chronic diseases in individuals over the age of 40 in São Paulo, Brazil: the Platino study

et al. 2012

View full text Add to dashboard Cite

“…Calculation of the contribution of loci to sibling relative risk was obtained using overall odds ratios and minor allele frequencies (77,78). Estimation of the fraction of variance explained was calculated using logistic regression and Nagelkerke's pseudo-R 2 (79) as implemented in R Design package, and alternatively using the estimates based on a liability threshold model by So et al (80) using a prevalence of COPD in smokers of 10% (81). LD was calculated for HapMap2 and 1000 Genomes CEU data using SNAP (82).…”

Section: Methodsmentioning

confidence: 99%

A Genome-Wide Association Study In COPD Identifies A Susceptibility Locus On Chromosome 19q13

Cho

Castaldi

Hersh

et al. 2011

A95. Cutting Edge Insights to the Pathobiology of Copd and Interstitial Lung Disease

Self Cite

View full text Add to dashboard Cite

The genetic risk factors for chronic obstructive pulmonary disease (COPD) are still largely unknown. To date, genome-wide association studies (GWASs) of limited size have identified several novel risk loci for COPD at CHRNA3/CHRNA5/IREB2, HHIP and FAM13A; additional loci may be identified through larger studies. We performed a GWAS using a total of 3499 cases and 1922 control subjects from four cohorts: the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE); the Normative Aging Study (NAS) and National Emphysema Treatment Trial (NETT); Bergen, Norway (GenKOLS); and the COPDGene study. Genotyping was performed on Illumina platforms with additional markers imputed using 1000 Genomes data; results were summarized using fixed-effect meta-analysis. We identified a new genomewide significant locus on chromosome 19q13 (rs7937, OR 5 0.74, P 5 2.9 3 10 29 ). Genotyping this single * Molecular Genetics, 2012, Vol. 21, No. 4 947-957 doi:10.1093/hmg/ddr524 Advance Access published on November 11, 2011nucleotide polymorphism (SNP) and another nearby SNP in linkage disequilibrium (rs2604894) in 2859 subjects from the family-based International COPD Genetics Network study (ICGN) demonstrated supportive evidence for association for COPD (P 5 0.28 and 0.11 for rs7937 and rs2604894), pre-bronchodilator FEV 1 (P 5 0.08 and 0.04) and severe (GOLD 3&4) COPD (P 5 0.09 and 0.017). This region includes RAB4B, EGLN2, MIA and CYP2A6, and has previously been identified in association with cigarette smoking behavior.

show abstract

“…The prevalence of chronic obstructive pulmonary disease (COPD) in Switzerland is approximately 10%, comparable to other European countries (1,2). COPD is associated with high morbidity, increased mortality and enormous economic costs (1,4).…”

Section: Introductionmentioning

confidence: 99%

Performance Measures in the Management of Chronic Obstructive Pulmonary Disease in Primary Care – A Retrospective Analysis

Kaufmann

Markun

Hasler

et al. 2015

Praxis

View full text Add to dashboard Cite

Leistungsmessgrössen in der Grundversorgung von Patienten mit COPD – eine Analyse Zusammenfassung. Hintergrund: Das Befolgen der Empfehlungen für ein gutes Management der chronisch-obstruktiven Lungenkrankheit (COPD) verbessert wichtige Endpunkte. Leistungsmessgrössen (LM) reflektieren die Qualität der Betreuung, dennoch existieren über die Dokumentation dieser Messgrössen bei COPD für die Grundversorgung kaum Daten. Ziel: Überprüfen der Dokumentation von COPD spezifischen Messgrössen in Grundversorgerpraxen des Kanton Zürich. Methode: Retrospektive Auswertung der Krankengeschichten von Patienten mit ärztlich diagnostizierter COPD, über einen Zeitraum von zwölf Monaten. Die Dokumentation der LM wurde durch Berechnen des Prozentsatzes der dokumentierten Parameter bewertet. Zusätzlich erfolgte ein Vergleich der LM Dokumentation mit einer Praxis, die ein strukturiertes COPD-Programm implementiert hatte. Resultate: Es wurden Daten von 115 Patienten aus 14 Praxen, davon 57% männlich, mit einem Durchschnittsalter von 68 (44–93) Jahren, analysiert. 46% waren aktive Raucher mit 56 (22–150 py) Packyears. Komorbiditäten waren in 73% der Fälle dokumentiert, der Schweregrad mit GOLD-Klassifizierung in 70% (GOLD I 11%, GOLD II 64%, GOLD III 21%, GOLD IV 4%).Gemäss Dokumentation hatten die Patienten durchschnittlich 1,4 Exazerbationen pro Jahr. Die Dokumentation der LM lag zwischen 16% (schriftlicher Aktionsplan im Falle von Exazerbationen) und 95% (Raucherstatus). Eine Dokumentation für eine Rauchstopp-Empfehlung fand sich in 74% der Fälle, für die Grippeimpfung in 49%. Eine adäquate medikamentöse Therapie und Instruktion der Inhalation war für 65 bzw. 57%, für pulmonale Rehabilitation in 27% der Patienten dokumentiert. Angaben zu einer kollaborativen und proaktiven Betreuung fanden sich bei 60 resp. 51%. Die Praxis mit dem laufenden COPD-Programm zeigte eine signifikant bessere Dokumentation (p<0,01) für alle LM ausser für die Grippeimpfung. Schlussfolgerung: In der Schweizer Grundversorgung bestehen Lücken in der Dokumentation hinsichtlich der Empfehlungen für eine nutzbringende COPD-Versorgung. Die Identifikation und Überbrückung dieser Lücken ist zentral für mehr Qualität in der Gesundheitsversorgung.

show abstract

International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study

Cited by 1,890 publications

References 28 publications

Prevalence of self-reported chronic diseases in individuals over the age of 40 in São Paulo, Brazil: the Platino study

Prevalence of self-reported chronic diseases in individuals over the age of 40 in São Paulo, Brazil: the Platino study

A Genome-Wide Association Study In COPD Identifies A Susceptibility Locus On Chromosome 19q13

Performance Measures in the Management of Chronic Obstructive Pulmonary Disease in Primary Care – A Retrospective Analysis

Contact Info

Product

Resources

About